IS IT RADIOTHERAPY NECESSARY FOR PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) PATIENTS ACHIEVING PET NEGATIVITY AFTER IMMUNOCHEMOTHERAPY? Hematol Oncol 2019. [DOI: 10.1002/hon.77_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]

EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMA, NASAL TYPE - CASE REPORT AND REVIEW OF CZECH LYMPHOMA STUDY GROUP (CLSG) DATABASE. Hematol Oncol 2019. [DOI: 10.1002/hon.157_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol 2019;94:E50-E53. [PMID: 30474171 DOI: 10.1002/ajh.25362] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 10/29/2018] [Accepted: 11/19/2018] [Indexed: 11/07/2022]

Potential loss of prognostic significance of minimal residual disease assessment after R‐CHOP‐based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. Hematol Oncol 2018;36:773-778. [DOI: 10.1002/hon.2550] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Revised: 08/03/2018] [Accepted: 08/11/2018] [Indexed: 01/18/2023]

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematol Oncol 2017;36:110-115. [DOI: 10.1002/hon.2483] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2017] [Revised: 09/26/2017] [Accepted: 09/27/2017] [Indexed: 11/07/2022]

DOUBLE-EXPRESSOR LYMPHOMAS DO NOT HAVE INFERIOR OUTCOME AFTER AUTOLOGOUS STEM-CELL TRANSPLANT IN THE FIRST LINE TREATMENT. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]

RITUXIMAB MAINTENANCE AFTER NORDIC PROTOCOL (R-MAXICHOP/HD-ARAC/ASCT) SIGNIFICANTLY PROLONGS SURVIVAL IN YOUNG MANTLE CELL LYMPHOMA PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]

SIMULTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT THE DIAGNOSIS HAS SIMILAR OUTCOME AS DLBCL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]